# City Therapeutics, Inc. (CTY)

> Source: Nexqual · https://nexqual.com/CTY · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, City Therapeutics, Inc. (CTY), nexqual.com/CTY" · informational, not investment advice.

**Price:** USD 20.77 (+1.66% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 20.43 · day 19.75–20.85 · 52w 19.75–23.88 · market cap $1.05B · NGM

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -7.3% vs S&P 500 +14.9%; 5Y -7.3% vs S&P 500 +80.3%.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2026-10-16) | 5Y (from 2026-10-12) |
|---|---|---|
| Total return | -7.3% | -7.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | — | — |
| Volatility (annualized) | 40.4% | 38.5% |
| Max drawdown | -8.8% (Oct 2026→Oct 2026) | -7.3% (Oct 2026→Oct 2026) |

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 307.82 -2.21% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 90.9 +2.57% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.14 -3.28% · PRAX (Praxis Precision Medicines, Inc) USD 258.92 +0.96% · IONS (Ionis Pharmaceuticals, Inc.) USD 43.91 -0.81% · ABVX (Abivax SA) USD 90.23 -3.49%

## More
Full page: https://nexqual.com/CTY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name CTY in their own reports (relationship from CTY's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | BIOGEN INC. (BIIB) | 10-K 2026-02-06 | "For additional information on our strategic research arrangement with City Therapeutics, please read Note 19, Collaborative and Other Relationships, to our consolidated financial statements included i…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |